X4 PHARMACEUTICALS, INC Business Acquisition, Pro Forma Net Income (Loss)
X4 PHARMACEUTICALS, INC (XFOR) reported Business Acquisition, Pro Forma Net Income (Loss) of -$57.82 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2020-03-12
- X4 PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for the quarter ending 2019-12-31 was -$10.94M.
- X4 PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for the quarter ending 2019-09-30 was -$17.71M.
- X4 PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for the quarter ending 2019-06-30 was -$12.90M.
- X4 PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for the quarter ending 2019-03-31 was -$16.26M.
- X4 PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for fiscal 2019 was -$57.82M.
- X4 PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for fiscal 2018 was -$76.25M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$10.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$28.66M derived: sum of 2 quarters · filed 2020-03-12 | -$41.56M derived: sum of 3 quarters · filed 2020-03-12 | -$57.82M 10-K · filed 2020-03-12 |
| 2019-09-30 | -$17.71M 10-Q · filed 2019-11-07 | -$30.62M derived: sum of 2 quarters · filed 2019-11-07 | -$46.88M 10-Q · filed 2019-11-07 | -$64.56M derived: sum of 4 quarters · filed 2020-03-12 |
| 2019-06-30 | -$12.90M 10-Q · filed 2019-08-07 | -$29.16M 10-Q · filed 2019-08-07 | -$46.85M derived: sum of 3 quarters · filed 2020-03-12 | -$66.56M derived: sum of 4 quarters · filed 2020-03-12 |
| 2019-03-31 | -$16.26M 10-Q · filed 2019-05-15 | -$33.94M derived: sum of 2 quarters · filed 2020-03-12 | -$53.66M derived: sum of 3 quarters · filed 2020-03-12 | -$72.27M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-12-31 | -$17.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$37.40M derived: sum of 2 quarters · filed 2020-03-12 | -$56.01M derived: sum of 3 quarters · filed 2020-03-12 | -$76.25M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$19.71M 10-Q · filed 2019-11-07 | -$38.33M derived: sum of 2 quarters · filed 2019-11-07 | -$58.56M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | -$18.62M 10-Q · filed 2019-08-07 | -$38.85M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | -$20.23M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |